Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Judith M VersluisStephanie A BlankensteinPetros DimitriadisJames S WilmottRobert ElensWilleke A M BlokxWinan van HoudtAlexander Maxwell MenziesYvonne M SchrageMichel W J M WoutersJoyce SandersAnnegien BroeksRichard A ScolyerKarlijn P M SuijkerbuijkGeorgina V LongAlexander C J van AkkooiChristian U BlankPublished in: Journal for immunotherapy of cancer (2024)
IFNγ has shown to be a prognostic marker in both patients who were and were not treated with adjuvant therapy. B cell score was prognostic but did not improve accuracy over IFNγ. Our study confirmed RFS benefit of adjuvant anti-PD-1 for patients with macroscopic stage III melanoma.